8-K: Soleno Therapeutics Submits NDA for Prader-Willi Syndrome Treatment and Reports Second Quarter 2024 Financial Results

Soleno Therapeutics announced the submission of a New Drug Application (NDA) to the FDA for Diazoxide Choline Extended-Release (DCCR) for Prader-Willi Syndrome (PWS) and reported its second quarter 2024 financial results.

Summary

• Soleno Therapeutics submitted a New Drug Application (NDA) to the FDA for Diazoxide Choline Extended-Release (DCCR) for the treatment of Prader-Willi Syndrome (PWS) in individuals four years and older with hyperphagia.
• The company completed an underwritten public offering of 3,450,000 shares of common stock at $46.00 per share, raising approximately $158.7 million.
• The FDA granted Breakthrough Therapy Designation for DCCR for the treatment of adults and children ages four years and older with genetically confirmed PWS who have hyperphagia.
• Soleno presented data from the randomized withdrawal period of Study C602 of DCCR in PWS at the Annual Meeting of the Endocrine Society (ENDO 2024).
• The company joined the Russell 3000 Index effective July 1, 2024.
• As of June 30, 2024, Soleno had $294.6 million in cash, cash equivalents, and marketable securities.
• Research and development expenses were $12.3 million for the three months and $26.9 million for the six months ended June 30, 2024, compared to $5.1 million and $10.5 million in the same periods of 2023.
• General and administrative expenses were $10.9 million for the three months and $19.4 million for the six months ended June 30, 2024, compared to $3.2 million and $6.0 million in the same periods of 2023.
• The fair value of the contingent liability for the Essentialis purchase price was estimated to be $13.6 million as of June 30, 2024.
• Total other income, net, was $3.0 million and $5.1 million for the three and six months ended June 30, 2024, respectively.
• Net loss was approximately $21.9 million and $43.3 million for the three and six months ended June 30, 2024, respectively.

Sentiment

Score: 6

Explanation: The document presents a mix of positive and negative aspects. The NDA submission and capital raise are positive, but the increased expenses and net loss are concerning. The overall sentiment is cautiously optimistic.

Positives

• The submission of the NDA for DCCR is a significant milestone for the company.
• The successful public offering has strengthened the company's balance sheet with $294.6 million in cash, cash equivalents, and marketable securities.
• The Breakthrough Therapy Designation from the FDA could expedite the review process for DCCR.
• The company is actively preparing for the potential launch of DCCR, including market access strategies and sales force planning.
• Soleno's inclusion in the Russell 3000 Index increases its visibility to investors.

Negatives

• The company experienced a significant increase in research and development expenses, rising to $12.3 million and $26.9 million for the three and six months ended June 30, 2024, respectively.
• General and administrative expenses also increased substantially to $10.9 million and $19.4 million for the three and six months ended June 30, 2024, respectively.
• The company reported a net loss of $21.9 million and $43.3 million for the three and six months ended June 30, 2024, respectively.
• The company has a contingent liability of $13.6 million related to the Essentialis merger.

Risks

• The FDA may not approve the NDA for DCCR.
• The company's interpretation of the data may not align with the FDA's assessment.
• Market conditions could impact the commercial success of DCCR.
• The company faces risks and uncertainties inherent in its business, as detailed in its SEC filings.
• The company's forward-looking statements are subject to various risks and uncertainties.

Future Outlook

The company is preparing for a potential launch of DCCR, including market access strategies, sales force sizing, and identifying medical education needs. Soleno is focused on advancing DCCR through late-stage clinical development and working with the FDA.

Management Comments

• Anish Bhatnagar, M.D., Chief Executive Officer of Soleno Therapeutics, stated that the second quarter of 2024 saw substantial progress for Soleno, highlighted by submission of an NDA to the FDA for DCCR.
• He also mentioned that the launch teams are diligently preparing for a potential launch of DCCR.

Industry Context

This announcement is significant for the rare disease therapeutics sector, as it represents a potential new treatment option for Prader-Willi Syndrome, a condition with no currently approved therapies for hyperphagia. The successful NDA submission and Breakthrough Therapy Designation could position Soleno as a key player in this space.

Comparison to Industry Standards

• Soleno's $158.7 million capital raise is substantial for a clinical-stage biotech company, comparable to other firms in the sector that are advancing late-stage clinical programs.
• The increase in R&D and G&A expenses is typical for a company preparing for a potential product launch, similar to other companies in the biopharmaceutical industry.
• The net loss is also typical for a company at this stage of development, as they are investing heavily in clinical trials and commercialization efforts.
• The contingent liability related to the Essentialis merger is a common feature in acquisitions within the biotech industry.

Stakeholder Impact

• Shareholders will be impacted by the financial results and the potential approval of DCCR.
• Employees will be involved in the preparation for the potential launch of DCCR.
• Patients with PWS and their families could benefit from a new treatment option.
• Creditors will be impacted by the company's financial performance.

Next Steps

• Soleno will continue to work with the FDA on the review of the NDA for DCCR.
• The company will continue to prepare for the potential launch of DCCR, including market access strategies and sales force planning.

Key Dates

Keywords

Prader-Willi Syndrome, DCCR, Diazoxide Choline, NDA, FDA, Hyperphagia, Rare Diseases, Clinical Stage, Biopharmaceutical, Public Offering, Breakthrough Therapy Designation, Russell 3000 Index